Document Detail


FDA LABA warning: is there anything new here?
MedLine Citation:
PMID:  20485319     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The FDA advisory on long-acting beta-agonists (LABAs) is not based on new data but on ongoing safety concerns about this class of medication. Not to be ignored are the potential safety risks of short-acting beta-agonists (SABAs).
Authors:
S T Weiss
Related Documents :
19552339 - The family and medical leave act: implications for occupational and environmental healt...
23047779 - Impact of part d low-income subsidies on medication patterns for medicare beneficiaries...
23816779 - Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
18018439 - Benign paroxysmal positional vertigo in an airline pilot.
24438709 - Combating medical device fouling.
23994199 - Drugs during delivery room resuscitation - what, when and why?
25386509 - Question vetting: the process to ensure quality in assessment of medical students.
10556729 - Salt stress affects sterol biosynthesis in the halophilic black yeast hortaea werneckii.
25137099 - Hiring scribes.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  87     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2010 Jun 
Date Detail:
Created Date:  2010-05-20     Completed Date:  2010-06-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  638-9     Citation Subset:  AIM; IM    
Affiliation:
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. scott.weiss@channing.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Inhalation
Adrenergic beta-Agonists / administration & dosage,  adverse effects*,  therapeutic use
Asthma / drug therapy
Delayed-Action Preparations
Drug Labeling*
Glucocorticoids / administration & dosage,  adverse effects,  therapeutic use
Humans
Practice Guidelines as Topic
United States
United States Food and Drug Administration
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Delayed-Action Preparations; 0/Glucocorticoids

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dealing with the evidence dilemma in genomics and personalized medicine.
Next Document:  Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?